These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36142299)

  • 41. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
    Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
    J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
    Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IGF-1R Inhibition Suppresses Cell Proliferation and Increases Radiosensitivity in Nasopharyngeal Carcinoma Cells.
    Wang Z; Liu G; Mao J; Xie M; Zhao M; Guo X; Liang S; Li H; Li X; Wang R
    Mediators Inflamm; 2019; 2019():5497467. PubMed ID: 31467485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
    Xu Y; Xie Z; Lu H
    J Cancer Res Ther; 2018 Jan; 14(1):103-105. PubMed ID: 29516969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
    Tam S; Al-Zubaidi Y; Rahman MK; Bourget K; Zhou F; Murray M
    Pharmacol Rep; 2022 Oct; 74(5):998-1010. PubMed ID: 35908023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib.
    Niehus SE; Tran DDH; Mischak M; Koch A
    Cell Signal; 2018 Nov; 51():191-198. PubMed ID: 30075184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
    Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
    J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
    Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
    Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
    Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
    Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.
    Jones HE; Gee JM; Barrow D; Tonge D; Holloway B; Nicholson RI
    Br J Cancer; 2006 Jul; 95(2):172-80. PubMed ID: 16819546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
    Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
    J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.